Comitato scientifico editoriale: Giuseppe Aprile, Consuelo Buttigliero, Paolo Carlini, Maria Vittoria Dieci, Massimo Di Maio, Raffaele Giusti, Sara Lonardi, Domenica Lorusso, Cristina Masini, Laura Noto, Silvia Novello, Filippo Pietrantonio, Giuseppe Procopio, Daniele Santini Editore: Intermedia – Direttore Responsabile: Mauro Boldrini
Oggi in Oncologia
The Probability of Aggressive Versus Indolent Histology Based on Renal Tumor Size: Implications for Surveillance and Treatment
While the probability of malignant versus benign histology based on renal tumor size has been described, this alone does not sufficiently inform decision-making in the modern era since indolent malignant tumors can be managed with active surveillance. To characterize the probability of aggressive versus indolent histology based on radiographic tumor size. We evaluated patients who underwent radical or partial nephrectomy at Mayo Clinic for a pT1-2, pNx/0, M0 … (leggi tutto)
Questo studio dimostra come le dimensioni di lesioni renali (oltre i 3 cm) in seguito ad un riscontro radiografico e il sesso maschile predicano un aumentato rischio di aggressività, ossia una istologia maligna e di alto grado, correlando anche con una peggiore sopravvivenza. La sorveglianza attiva inoltre va proposta in maniera cautelativa e non è ancora chiaro a chi può essere proposta in quanto in questa larga coorte di pazienti la maggior parte di coloro che non viene trattata all’esordio va incontro alla chirurgia dopo 3-6 mesi dalla diagnosi.
Cisplatin-Based First-Line Treatment of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: Joint Analysis of MILES-3 and MILES-4 Phase III Trials
To test the efficacy of adding cisplatin to first-line treatment for elderly patients with advanced non–small-cell lung cancer (NSCLC) within a combined analysis of two parallel phase III trials, MILES-3 and MILES-4. Patients with advanced NSCLC who were older than age 70 years with Eastern Cooperative Oncology Group performance status 0 to 1 were randomly assigned to gemcitabine or pemetrexed, without or with cisplatin. In each trial, 382 events were required to … (leggi tutto)
Da parte di uno dei gruppi che negli ultimi 20 anni a livello mondiale ha dato maggiori indicazioni in questo sottogruppo di pazienti arriva la conferma ad un dato già abbastanza solido in letteratura, ossia che l’aggiunta del cisplatino alla prima linea di trattamento nei pazienti anziani con tumore polmonare non a piccole cellule (NSCLC) in stadio avanzato (e senza mutazioni attivanti di EGFR) non sia di alcun beneficio. La considerazione deriva da un’analisi degli studi MILES-3 e MILES-4 che valutavano, rispettivamente nel NSCLC e nell’istologia non squamosa, l’aggiunta del cisplatino nei pazienti naïve anziani in stadio IV di malattia. I due studi purtroppo venivano chiusi precocemente per un rallentamento nell’arruolamento, ma la valutazione di entrambe le casistiche consente di fornire un’indicazione solida. 531 sono i pazienti analizzati (MILES-3 = 299, MILES-4 = 232), randomizzati nel periodo fra Marzo 2011 e Agosto 2016 a ricevere gemcitabina e pemetrexed in associazione (n = 263) o senza (n = 268) cisplatino. La popolazione riporta un’età media di 75 anni, 79% maschi, 70% con istologia non squamousa. Con un follow-up mediano di 2 anni la sopravvivenza globale descritta è pari a 9,6 mesi con la terapia di combinazione verso 7,5 mesi per la monoterapia (hazard ratio [HR] = 0,86; p = 0,14). La Qualità di Vita testate con il questionario EORTC QLQ-C30 non rivela alcuna differenza fra i due gruppi. La sopravvivenza libera da progressione mediana è di 4,6 mesi con la terapia di combinazione verso 3,0 mesi con monoterapia (HR = 0,76; p = 0,005). I tassi di risposta sono 15.5% vs 8.5% (p = 0,02). I pazienti trattati con cisplatino riportavano una significativa maggiore tossicità in termini di tossicità ematologica, neurologia, mucositi, vomito, nausea, trombocitopenia, leucopenia, neutropenia, neutropenia febbrile, fatigue, anoressia. L’introduzione dell’immunoterapia nella prima linea di trattamento ha certamente rivoluzionato l’approccio terapeutico nei pazienti affetti da NSCLC in stadio avanzato, compresi quelli anziani, ma indubbiamente il dato qui presentato resta attuale in considerazione del fatto che molto presto avremo anche l’opzione di trattamento con chemioterapia addizionata ad immunoterapia, ma con sole informazioni sull’intera popolazione (fatta eccezione per valutazioni per sottogruppi) e con la sola chemioterapia.
Super-resolution T2-weighted 4D MRI for image guided radiotherapy
The superior soft-tissue contrast of 4D-T2w MRI motivates its use for delineation in radiotherapy treatment planning. We address current limitations of slice-selective implementations, including thick slices and artefacts originating from data incompleteness and variable breathing. A method was developed to calculate midposition and 4D-T2w images of the whole thorax from continuously acquired axial and sagittal 2D-T2w MRI (1.5×1.5×5.0mm3). The method employed … (leggi tutto)
Dall’Institute of Cancer Research di Londra e dalla Royal Marsden NHS Foundation Trust vengono creati video ad alta risoluzione a partenza da immagini di torace di volontari sani utilizzando immagini bidimensionali di risonanza magnetica (MRI). Con questa tecnica è possibile ricavare immagini che sono cinque volte più precise e dettagliate rispetto a qualunque altra metodica MRI. Questo potenzialmente ha un impiego unico nella pianificazione del piano di cura dei radioterapisti con un riadattamento in corso di cura. Lo studio, partendo da 8 volontari sani arriva a riprodurre immagini di sezioni corporee in tutte le posizioni e vari punti di osservazione. Questo dovrebbe favorire il lavoro dei radioterapisti che al momento fanno un piano cure basato su immagini CT. Potenzialmente questo è di indubbio vantaggio e può rendere molto più precisa l’erogazione. Va peraltro considerato che questa tecnica radiologica non è parte del processo diagnostico e di staging per il tumore polmonare e che si tratterebbe quindi di un esame “aggiunto”.
Projections in Breast and Lung Cancer Mortality among Women: A Bayesian Analysis of 52 Countries Worldwide
Among women, lung cancer mortality rates have surpassed those for breast cancer in several countries. This reflects the breast cancer mortality declines due to access to screening and effective treatment alongside the entrance of certain countries in stages of the tobacco epidemic in which smoking becomes more prevalent in women. In this study, we project lung and breast cancer mortality until 2030 in 52 countries. Cancer mortality data were obtained from the … (leggi tutto)
Qualora i dati attuali non fossero già sufficientemente preoccupanti, questo lavoro pubblicato su Cancer Research parla di un aumento di mortalità per il tumore polmonare fra le donne del 43% entro il 2030 a fronte di un decremento del dato per il tumore mammario del 9%. Nei Paesi a maggior introito, la mortalità per tumore polmonare supererà quella per tumore mammario. In considerazione del fatto che l’utilizzo della TC spirale come metodo di prevenzione secondaria non trova ad oggi né un consenso né un’applicazione globale, difficilmente questo sarà il metodo per frenare questa crescita che dovrà pertanto esser controllata da adeguate campagne di prevenzione primaria, cessazione tabagica e sensibilizzazione. I dati sono stati ottenuti da una valutazione del WHO Mortality Database dal 2008 al 2014, tenendo in considerazione Paesi, età, anno di valutazione. Sono stati valutati i Paesi con una popolazione superiore al milione. 52 Paesi sono stati analizzati di cui 29 in Europa, 14 nelle Americhe, 7 in Asia e 2 in Oceania. Il tasso di mortalità standardizzato per età (age-standardized mortality rate: ASMR) per il tumore polmonare e mammario è stato calcolato per ogni Paese attraverso il modello Bayesiano log-linear Poisson. Per il tumore polmonare viene descritto un incremento dell’ASMR dall’11,2% del 2015 al 16 nel 2030 con le proiezioni più elevate in Europa ed Oceania rispetto ad Americhe e Asia. Per il tumore mammario ci si aspetta invece una riduzione dell’ASMR dal 16,1% del 2015 al 14,7% nel 2030. La più alta mortalità anche in questo caso in Europa e i valori più bassi in Asia. Gli investimenti nelle campagne contro il fumo si rivelano ancora una volta indispensabili e cruciali anche per bloccare questo disastroso incremento.
Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix
To assess if the combination of topotecan, paclitaxel, and bevacizumab (TPB) was active in recurrent SCCC and to compare the survival of patients with SCCC who received TPB to a group of women with SCCC who did not receive this regimen. We retrospectively analyzed women with recurrent SCCC who received chemotherapy as primary therapy. Women treated with TPB for first recurrence were compared to women treated with non-TPB chemotherapy. Thirteen … (leggi tutto)
Lo studio riporta i dati di efficacia e tossicità di una combinazione a tre farmaci in un tumore ultra raro e a cattiva prognosi come il tumore neuroendocrino della cervice uterina. Lo studio retrospettivo confronta 13 pazienti trattate con la combinazione sperimentale di topotecan, taxolo, bevacizumab con una serie storica di 21 pazienti trattate con le più varie chemioterapie (non esiste uno standard di seconda linea in questo tumore) e riporta un vantaggio di sopravvivenza libera da progressione, ma non di sopravvivenza globale nelle pazienti trattate con la combinazione sperimentale (7,8 vs 4,0 mesi) con, in aggiunta, un significativo numero di pazienti riportanti un duraturo beneficio clinico (62% di controllo di malattia a 6 mesi). Gli autori concludono che la combinazione ha un potenziale impatto in un tumore rarissimo e a cattiva prognosi e nella pratica clinica potrebbe essere oggetto di un utilizzo off label del bevacizumab.
In Europa
Lenvatinib Approved in Europe for Frontline HCC
August 23, 2018 – The European Commission has approved lenvatinib as a first-line treatment for adult patients with advanced or unresectable hepatocellular carcinoma (HCC). The approval was based on data from the phase III REFLECT trial, which were published in February 2018 in the Lancet. In the trial, the multikinase inhibitor lenvatinib showed noninferiority to the established first-line standard of care, sorafenib. The median overall survival (OS) by … (leggi tutto)
New ESMO Tumor DNA Scale Helps Match Patients to Optimal Targeted Treatments
August 22, 2018 – A new scale for tumor DNA mutations called ESCAT (European Society for Medical Oncology [ESMO] Scale for Clinical Actionability of Molecular Targets) is aiming to simplify and standardize choices for targeted cancer treatment. Information about the development and use of the scale in practice was published by Mateo et al in Annals of Oncology. The goal of the use of ESCAT is to optimize patient care by making it easier to identify patients with cancer … (leggi tutto)
Brexit preparedness: EMA to further temporarily scale back and suspend activities
August 1, 2018 – The European Medicines Agency (EMA) will launch the next phase of its business continuity plan on 1 October 2018 at the latest. This will allow the Agency to safeguard core activities related to the evaluation and supervision of medicines, while it has to intensify its preparations for the physical move to Amsterdam in March 2019 and cope with significant staff loss. The temporary cuts in activities are required because it has also become clear … (leggi tutto)
EU Approves Trastuzumab Biosimilar for HER2+ Breast, Gastric Cancers
August 1, 2018 – PF-05280014, a biosimilar for trastuzumab, has been approved for use in the European Union (EU) to treat patients with HER2 overexpressing metastatic or early breast cancer and HER2 overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. The EU’s Committee for Medicinal Products for Human Use issued a positive opinion on PF-05280014 in May. Pfizer, the manufacturer of PF-05280014, issued a release announcing the … (leggi tutto)
Adjuvant Nivolumab Approved in Europe for Melanoma
July 31, 2018 – The European Commission has approved nivolumab as an adjuvant treatment for adult patients with completely resected melanoma with lymph node involvement or metastatic disease, regardless of BRAF mutation status. The approval was based on findings from the randomized phase III CheckMate-238 trial, in which the recurrence-free survival (RFS) rate at 18 months with nivolumab was 66.4% (95% CI, 61.8%-70.6%) compared with 52.7% … (leggi tutto)
Pembrolizumab Nears European Approval for HNSCC
July 30, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of pembrolizumab for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) who progressed following platinum-based chemotherapy and have a PD-L1 tumor proportion score (TPS) ≥50%.The CHMP recommendation is based on data from the phase III KEYNOTE-040 … (leggi tutto)
EU Panel Backs Frontline Pembrolizumab Combo for Nonsquamous NSCLC
July 30, 2018 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of frontline pembrolizumab for use in combination with standard chemotherapy for patients with metastatic nonsquamous non-small cell lung cancer (NSCLC) without EGFR or ALK mutations, regardless of PD-L1 expression. The CHMP recommendation is based on the phase III KEYNOTE-189 trial, in which patients with … (leggi tutto)
Dall’FDA
FDA Grants Fast Track Designation to AVB-S6-500 for Platinum-Resistant Ovarian Cancer
August 23, 2018 – The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AVB-S6-500 as a potential treatment for platinum-resistant recurrent ovarian cancer. AVB-S6-500 is a novel high-affinity, soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. Research has shown GAS6-AXL signaling to be a key molecular pathway that promotes … (leggi tutto)
FDA Grants Elotuzumab Triplet Priority Review for Myeloma
August 23, 2018 – The FDA has granted a priority review to a supplemental biologics license application (sBLA) for elotuzumab for use in combination with pomalidomide and low-dose dexamethasone (EPd) for the treatment of patients with relapsed/refractory multiple myeloma following 2 or more prior therapies, including lenalidomide and a proteasome inhibitor (PI). The sBLA was submitted based on the phase II ELOQUENT-3 trial, in which the addition of elotuzumab … (leggi tutto)
FDA Grants Orphan Drug Designation to ASLAN003 in Acute Myeloid Leukemia
August 22, 2018 – The U.S. Food and Drug Administration (FDA) has granted ASLAN003 Orphan Drug designation as a treatment for acute myeloid leukemia (AML). ASLAN003 is an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a first-in-class drug in AML. The FDA grants Orphan Drug designation to agents intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the … (leggi tutto)
FDA Grants Orphan Drug Designation to CPI-613 for the Treatment of Peripheral T-Cell Lymphoma
August 21, 2018 – The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to CPI-613 for the treatment of peripheral T-cell lymphoma. CPI-613 is a novel lipoic acid analog with an anticancer activity that inhibits multiple enzyme targets within the tricarboxylic acid cycle. This drug is currently under investigation in combination with bendamustine in patients with relapsed or refractory T-cell lymphoma. T-cell lymphomas account for 10% to … (leggi tutto)
FDA Approves Pembrolizumab in Combination With Chemotherapy for First-Line Treatment of Metastatic Nonsquamous NSCLC
August 20, 2018 – Today, the U.S. Food and Drug Administration (FDA) approved pembrolizumab in combination with pemetrexed and platinum as first-line treatment of patients with metastatic, nonsquamous non-small cell lung cancer with no EGFR or ALK genomic tumor aberrations. Pembrolizumab was previously granted accelerated approval for this indication in May 2017 based on improvements in overall response rate and progression-free survival for patients … (leggi tutto)
FDA Updates Prescribing Information for Pembrolizumab and Atezolizumab in Urothelial Carcinoma
August 20, 2018 – On August 16, 2018, the U.S. Food and Drug Administration (FDA) updated the prescribing information for pembrolizumab and atezolizumab to require the use of an FDA-approved companion diagnostic test to determine programmed cell death ligand 1 (PD-L1) levels in tumor tissue from patients with locally advanced or metastatic urothelial cancer who are ineligible for cisplatin therapy. The FDA approved two different companion diagnostic tests … (leggi tutto)
FDA Approves Nivolumab for Certain Patients With Previously Treated Small Cell Lung Cancer
August 17, 2018 – Today, nivolumab received approval from the U.S. Food and Drug Administration (FDA) for patients with metastatic small cell lung cancer (SCLC) whose cancer has progressed after platinum-based chemotherapy and at least one other line of therapy. Approval for this indication has been granted under accelerated approval based on overall response rate and duration of response. This approval for nivolumab had been granted Priority Review from the … (leggi tutto)
FDA Approves Lenvatinib for Unresectable Hepatocellular Carcinoma
August 16, 2018 – Today, the U.S. Food and Drug Administration (FDA) approved lenvatinib capsules for first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Approval was based on the international, multicenter, randomized, open-label, noninferiority REFLECT trial conducted in 954 patients with previously untreated, metastatic, or unresectable HCC. Patients were randomized 1:1 to receive lenvatinib (12 mg orally once daily for patients … (leggi tutto)
FDA Grants Breakthrough Device Designation for Cancer Detection Liquid Biopsy
August 14, 2018 – PapGene, Inc, has announced their cancer detection test has received Breakthrough Device designation from the Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (FDA). The PapGene test is a multianalyte test that uses a combination of circulating tumor DNA (ctDNA) and protein biomarkers to detect the presence of cancer in average-risk, asymptomatic individuals over the age of 65 years old. The FDA .. (leggi tutto)
FDA Grants SL-401 Priority Review for Rare Hematologic Cancer
August 13, 2018 – The FDA has granted a priority review designation to a biologics license application (BLA) for SL-401 (tagraxofusp) for the treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), according to Stemline Therapeutics, the developer of the novel stemness inhibitor. The drug is directed at the IL-3 receptor, which is overexpressed on cancer stem cells and/or tumor bulk in many hematologic malignancies. SL-401 is being investigated as … (leggi tutto)
FDA Approves Mogamulizumab for CTCL
August 8, 2018 – The FDA has approved mogamulizumab-kpkc for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least 1 prior systemic therapy. The approval is specifically for patients with mycosis fungoides (MF) or Sézary syndrome (SS), 2 subtypes of CTCL. The FDA based its decision on findings from the phase III MAVORIC study. Results from the study presented at the 2017 ASH Annual Meeting showed that mogamulizumab … (leggi tutto)
Selinexor FDA Submission Completed for Multiple Myeloma
August 7, 2018 – A rolling submission of an FDA new drug application (NDA) has been completed for selinexor for the treatment of patients with penta-refractory multiple myeloma, according to Karyopharm Therapeutics, the manufacturer of the XPO1 inhibitor. The NDA is based on results from part 2 of the phase IIb STORM trial, in which selinexor induced an overall response rate (ORR) of 25.4% in patients with penta-refractory multiple myeloma. The responses included … (leggi tutto)
FDA Grants Novel Triplet Breakthrough Designation in BRAF+ mCRC
August 7, 2018 – The FDA has granted a breakthrough therapy designation to the combination of the BRAF inhibitor encorafenib, the MEK inhibitor binimetinib, and the EGFR inhibitor cetuximab for the treatment of patients with BRAF V600E–mutant metastatic colorectal cancer (mCRC) following 1 or 2 prior lines of treatment in the metastatic setting. The designation, which will expedite the development and review of the novel triplet in this setting, is based on … (leggi tutto)
FDA Grants Lurbinectedin Orphan Drug Status for SCLC
August 6, 2018 – The FDA has granted lurbinectedin (PM1183) an orphan drug designation for the treatment of patients with small cell lung cancer (SCLC), according to PharmaMar, the manufacturer of the marine-derived treatment. The Orphan Drug program is intended to facilitate the development and review of novel therapies for the treatment of patients with rare diseases or conditions that affect fewer than 200,000 people in the United States. Data were presented at the … (leggi tutto)
FDA Grants Orphan Drug Designation to SRF231 for Treatment of Multiple Myeloma
August 2, 2018 – The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to SRF231 for the treatment of patients with multiple myeloma. SRF231 is a fully human antibody that inhibits the activity of CD47, a protein overexpressed on many types of cancer cells, which prevents them from being engulfed and eliminated by macrophages. “While the potential applications for SRF231 in oncology are quite broad, we are particularly excited about … (leggi tutto)
FDA Grants Breakthrough Status to Lenvatinib/Pembrolizumab for Endometrial Cancer
August 1, 2018 – The FDA has granted a breakthrough therapy designation to the combination of lenvatinib and pembrolizumab for the treatment of patients with advanced and/or metastatic non–microsatellite instability high (MSI-H)/proficient mismatch repair endometrial carcinoma who have progressed after ≥1 prior systemic therapy. The designation, which will expedite the development and review of the combination in this setting was based on interim data … (leggi tutto)
FDA Grants Quizartinib Breakthrough Designation for FLT3-ITD+ AML
August 1, 2018 – The FDA has granted a breakthrough therapy designation to quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia (AML), according to Daiichi Sankyo, the manufacturer of the FLT3 inhibitor. The designation, which will expedite the development and review of quizartinib in this setting, is based on findings from the phase III QuANTUM-R study, in which the FLT3 inhibitor reduced the risk of disease … (leggi tutto)
FDA approves first treatment for rare adrenal tumors
July 30, 2018 – The U.S. Food and Drug Administration today approved iobenguane I-131 injection for intravenous use for the treatment of adults and adolescents age 12 and older with rare tumors of the adrenal gland (pheochromocytoma or paraganglioma) that cannot be surgically removed (unresectable), have spread beyond the original tumor site and require systemic anticancer therapy. This is the first FDA-approved drug for this use. “Many patients with these … (leggi tutto)
FDA Grants Fast Track Designation to Galinpepimut-S in Multiple Myeloma
July 30, 2018 – The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to galinpepimut-S for the treatment of multiple myeloma. Galinpepimut-S is licensed from Memorial Sloan Kettering Cancer Center and targets the Wilms tumor 1 (WT1) protein, which is present in an array of tumor types. Final clinical and immunologic data from a phase II clinical trial for galinpepimut-S in the treatment of high-risk multiple myeloma was presented at the 44th … (leggi tutto)
Dall’ASCO
Two Cancer Research Organizations Submit Recommendations to FDA Aimed at Reducing Barriers to Clinical Trial Participation
August 9, 2018 – The American Society of Clinical Oncology, Inc. (ASCO®) and Friends of Cancer Research (Friends) have submitted to the Food and Drug Administration (FDA) recommended language for five guidance documents on ways to broaden eligibility criteria for cancer clinical trials. The recommendations are part of an ASCO and Friends collaboration to broaden eligibility for participating in clinical trials by addressing five specific areas: minimum age … (leggi tutto)
ASCO Adds New Combos for Metastatic Noncastrate Prostate Cancer
July 31, 2018 – Use of androgen deprivation therapy (ADT) in combination with docetaxel or abiraterone in newly diagnosed cases of metastatic noncastrate prostate cancer (mNCPC) is recommended in recently updated American Society of Clinical Oncology (ASCO) guidelines. Historically, mNCPC has been treated with ADT alone until progression; ASCO noted a survival benefit from adding docetaxel or abiraterone, based on a review of several trials … (leggi tutto)
Dal mondo
Frontline Osimertinib Approved in Japan for NSCLC
August 22, 2018 – The Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved osimertinib for the frontline treatment of patients with inoperable or recurrent EGFR-positive non–small cell lung cancer (NSCLC), according to AstraZeneca, the manufacturer of the EGFR inhibitor. The approval is based on the phase III FLAURA study, in which frontline osimertinib reduced the risk of disease progression or death by 54% versus standard TKI therapy … (leggi tutto)
Alectinib Approved in China for ALK+ NSCLC
August 21, 2018 – The China National Drug Administration (CNDA) has approved alectinib for the treatment of patients with ALK-positive, advanced non–small cell lung cancer (NSCLC), according to Roche, the manufacturer of the second-generation ALK inhibitor. The approval was based on the primary analysis of the phase III ALEX study, in which frontline alectinib reduced the risk of disease progression or death by 53% versus crizotinib in patients with ALK- … (leggi tutto)
Pillole dall’Aifa
24 agosto 2018 – Nuova procedura di tracciatura prezzi nell’applicativo registri
La Sezione Regionale AIOM Liguria ha istituito il Premio ‘Giovanni Gardin’ 2018, riservato a Giovani Oncologi di età non superiore ai 40 anni (nell’anno solare in corso), quale riconoscimento per i migliori progetti su argomenti a cui il dottor Giovanni Gardin ha dedicato parte della propria attività clinica.
I premi saranno due, uno dedicato a un progetto su ‘I Tumori Cerebrali in Liguria’ e l’altro dedicato a un progetto sulla ‘Identificazione di Fattori Prognostici/Predittivi nei Tumori Solidi in Setting Adiuvante o Avanzato’. A ciascuno dei due migliori progetti di studio presentati sarà assegnato un premio pari a 4.000 Euro (al lordo della ritenuta fiscale). I premi saranno assegnati in occasione del Congresso Regionale AIOM Liguria.
Dal Soroptimist International Club Genova a favore delle ragazze STEM
Il Premio, del valore di 2.000 Euro, sarà attribuito ad una Tesi di Laurea Magistrale in campo Emato-Oncologico, discussa da una studentessa dell’Università degli Studi di Genova negli anni accademici 2016-17 o 2017-18, in una delle seguenti discipline: Medicina e Chirurgia – Scienze infermieristiche e ostetriche, Scienze riabilitative delle professioni sanitarie – Psicologia – Biologia – Scienze chimiche – Fisica – Farmaci e farmacia industriale – Biotecnologie mediche, veterinarie e farmaceutiche – Ingegneria biomedica.
Le domande dovranno essere inviate entro il 31 marzo 2019 ed il Premio sarà assegnato a giugno 2019.
Per scaricare il Bando e la Scheda di Partecipazione, vai al sito web.
Preserva la tua fertilità
Scheda informativa condivisa da ISS, PMA, AIMAC e AIOM
Suggerimenti semplici su come preservare la fertilità prima dei trattamenti antitumorali, cofirmati da Istituto Superiore di Sanità (ISS), Registro Nazionale di Procreazione Medicalmente Assistita (PMA), Associazione Italiana Malati di Cancro, parenti e amici (AIMaC) e Associazione Italiana di Oncologia Medica (AIOM), sono stati inclusi in una locandina. Contiene consigli e tecniche utilizzate in donne, uomini e bambini, in forma sintetica. Ulteriori informazioni sono disponibili ai siti web di ISS, AIMaC e AIOM oppure al numero verde AIMaC 840503579.
RETE ONCOLOGICA E FOCUS SUL PERCORSO DIAGNOSTICO TERAPEUTICO ASSISTENZIALE DEL PAZIENTE CON CARCINOMA POLMONARE
Rionero in Vulture (PZ), 21 settembre 2018 Convegno Regionale AIOM Basilicata Scadenza adesioni: 14 settembre 2018 Scarica la scheda di adesione dal sito AIOM
Editore: Intermedia s.r.l. – Via Malta 12/b, 25124 Brescia – tel. 030 226105 fax 030 2420472 – Reg. Trib. di Brescia n. 35/2001 del 2/7/2001 Per contattare la redazione e commentare le notizie clicca qui: redazione Per consultare i numeri arretrati della newsletter clicca qui: archivio Per sospendere la ricezione di questa newsletter clicca qui: AIOM news RIMUOVI